The role of oxytocin in cardiovascular regulation

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 3, 2014, Pages 206-214

  Gutkowska, J ^a   Jankowski, M ^a   Antunes Rodrigues, J ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiomyogenesis; Heart; Natriuretic peptides; Oxytocin

Indexed keywords

2, 4 DINITROPHENOL; ACETYLCHOLINE; ATRIAL NATRIURETIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; DIACYLGLYCEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INOSITOL PHOSPHATE; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN HEAVY CHAIN BETA; NITRIC OXIDE; OXYTOCIN; OXYTOCIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C BETA; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOIC ACID; STAT3 PROTEIN; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; CARDIOTONIC AGENT; OXYTOCIN RECEPTOR, RAT;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLOOD PRESSURE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONOTROPISM; CIRCULATION REGULATION; DIURESIS; GENE EXPRESSION; GLUCOSE TRANSPORT; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HYPERTROPHY; INOTROPISM; NATRIURESIS; NEUROHYPOPHYSIS; NEUROMODULATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION; ANIMAL; BLOOD; HEART; METABOLISM; PHYSIOLOGY; RAT;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENTS; CELL DIFFERENTIATION; HEART; HUMANS; MYOCYTES, CARDIAC; NITRIC OXIDE; OXIDATIVE STRESS; OXYTOCIN; RATS; RECEPTORS, OXYTOCIN; SIGNAL TRANSDUCTION;

EID: 84898896689     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20133309     Document Type: Review

References (75)

1. Oliver G, Schafer EA. On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication. J Physiol 1895; 18: 277-279.
2. Dale HH. On some physiological actions of ergot. J Physiol 1906; 34: 163-206.
3. Dale HH. The action of extracts of the pituitary body. Biochem J 1909; 4: 427-447.
4. Woodbury AR, Volpitto PP, Hamilton WF. Blood pressure studies of the effects of pituitary preparations on the human. Am J Physiol 1940; 129: 500.
5. Woodbury RA, Hamilton WF, Volpitto PP, Abreu BE, Harper HT. Cardiac and blood pressure effects of pitocin (oxytocin) in man. J Pharmacol 1944; 81: 95-100.
6. Nakano J, Fisher RD. Studies on the cardiovascular effects of synthetic oxytocin. J Pharmacol Exp Ther 1963; 142: 206-214.
7. Ott I, Scott JC. The action of infundibulin upon the mammary secretion. Proc Soc Exp Biol Med 1910; 8: 48-49. doi: 10.3181/00379727-8-27.
8. Paton DN, Watson A. The actions of pituitrin, adrenalin and barium on the circulation of the bird. J Physiol 1912; 44: 413-424.
9. von den Velden R. [Die Nierenwirkung von Hypophysenextrakten beim Menschen]. Klin Wochschr 1913; 50: 2083-2086.
10. Van Dyke HB. The regulation of water excretion by the neurohypophysis. Bull N Y Acad Med 1953; 29: 24-33.
11. Du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J Biol Chem 1953; 205: 949-957.
12. Du Vigneaud V. Trail of sulfur research: from insulin to oxytocin. Science 1956; 123: 967-974. doi: 10.1126/ science.123.3205.967.
13. Zhang H, Wu C, Chen Q, Chen X, Xu Z, Wu J, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS One 2013; 8: e61477. doi: 10.1371/journal.pone.0061477.
14. Sofroniew MV, Weindl A, Schrell U, Wetzstein R. Immunohistochemistry of vasopressin, oxytocin and neurophysin in the hypothalamus and extrahypothalamic regions of the human and primate brain. Acta Histochem Suppl 1981; 24: 79-95.
15. Gaida W, Lang RE, Kraft K, Unger T, Ganten D. Altered neuropeptide concentrations in spontaneously hypertensive rats: cause or consequence? Clin Sci 1985; 68: 35-43.
16. Van Tol HH, van den Buuse M, de Jong W, Burbach JP. Vasopressin and oxytocin gene expression in the supraoptic and paraventricular nucleus of the spontaneously hypertensive rat (SHR) during development of hypertension. Brain Res 1988; 464: 303-311.
17. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94. doi: 10.1016/0024-3205(81)90370-2.
18. Gutkowska J, Antunes-Rodrigues J, McCann SM. Atrial natriuretic peptide in brain and pituitary gland. Physiol Rev 1997; 77: 465-515.
19. Baldissera S, Menani JW, dos Santos LF, Favaretto AL, Gutkowska J, Turrin MQ, et al. Role of the hypothalamus in the control of atrial natriuretic peptide release. Proc Natl Acad Sci U S A 1989; 86: 9621-9625. doi: 10.1073/ pnas.86.23.9621.
20. Antunes-Rodrigues J, Ramalho MJ, Reis LC, Menani JV, Turrin MQ, Gutkowska J, et al. Lesions of the hypothalamus and pituitary inhibit volume-expansion-induced release of atrial natriuretic peptide. Proc Natl Acad Sci U S A 1991; 88: 2956-2960. doi: 10.1073/pnas.88.7.2956.
21. Haanwinckel MA, Elias LK, Favaretto AL, Gutkowska J, McCann SM, Antunes-Rodrigues J. Oxytocin mediates atrial natriuretic peptide release and natriuresis after volume expansion in the rat. Proc Natl Acad Sci U S A 1995; 92: 7902-7906. doi: 10.1073/pnas.92.17.7902.
22. Soares TJ, Coimbra TM, Martins AR, Pereira AG, Carnio EC, Branco LG, et al. Atrial natriuretic peptide and oxytocin induce natriuresis by release of cGMP. Proc Natl Acad Sci U S A 1999; 96: 278-283. doi: 10.1073/pnas.96.1.278.
23. Favaretto AL, Ballejo GO, Albuquerque-Araujo WI, Gutkowska J, Antunes-Rodrigues J, McCann SM. Oxytocin releases atrial natriuretic peptide from rat atria in vitro that exerts negative inotropic and chronotropic action. Peptides 1997; 18: 1377-1381. doi: 10.1016/S0196-9781(97)00209-X.
24. Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A 1997; 94: 11704-11709. doi: 10.1073/pnas.94.21.11704.
25. Jankowski M, Hajjar F, Kawas SA, Mukaddam-Daher S, Hoffman G, McCann SM, et al. Rat heart: a site of oxytocin production and action. Proc Natl Acad Sci U S A 1998; 95: 14558-14563. doi: 10.1073/pnas.95.24.14558.
26. Jankowski M, Wang D, Hajjar F, Mukaddam-Daher S, McCann SM, Gutkowska J. Oxytocin and its receptors are synthesized in the rat vasculature. Proc Natl Acad Sci U S A 2000; 97: 6207-6211. doi: 10.1073/pnas.110137497.
27. Adan RA, van Leeuwen FW, Sonnemans MA, Hoffman G, Verbalis JG, Burbach JP. The rat oxytocin receptor. cDNA cloning and immunocytochemical localization in brain, pituitary, mammary gland and uterus. Adv Exp Med Biol 1995; 395: 345-346.
28. Cicutti NJ, Smyth CE, Rosaeg OP, Wilkinson M. Oxytocin receptor binding in rat and human heart. Can J Cardiol 1999; 15: 1267-1273.
29. Jankowski M, Danalache B, Wang D, Bhat P, Hajjar F, Marcinkiewicz M, et al. Oxytocin in cardiac ontogeny. Proc Natl Acad Sci U S A 2004; 101: 13074-13079. doi: 10.1073/ pnas.0405324101.
30. Zingg HH, Laporte SA. The oxytocin receptor. Trends Endocrinol Metab 2003; 14: 222-227. doi: 10.1016/S1043-2760(03)00080-8.
31. Szeto A, Nation DA, Mendez AJ, Dominguez-Bendala J, Brooks LG, Schneiderman N, et al. Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab 2008; 295: E1495-E1501. doi: 10.1152/ajpendo. 90718.2008.
32. Cattaneo MG, Lucci G, Vicentini LM. Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. Exp Cell Res 2009; 315: 3210-3219. doi: 10.1016/ j.yexcr.2009.06.022.
33. Noiseux N, Borie M, Desnoyers A, Menaouar A, Stevens LM, Mansour S, et al. Preconditioning of stem cells by oxytocin to improve their therapeutic potential. Endocrinology 2012; 153: 5361-5372. doi: 10.1210/en.2012-1402.
34. Florian M, Jankowski M, Gutkowska J. Oxytocin increases glucose uptake in neonatal rat cardiomyocytes. Endocrinology 2010; 151: 482-491. doi: 10.1210/en.2009-0624.
35. Kobayashi H, Yasuda S, Bao N, Iwasa M, Kawamura I, Yamada Y, et al. Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis. J Cardiovasc Pharmacol 2009; 54: 510-519. doi: 10.1097/FJC.0b013e 3181bfac02.
36. Jankowski M, Bissonauth V, Gao L, Gangal M, Wang D, Danalache B, et al. Anti-inflammatory effect of oxytocin in rat myocardial infarction. Basic Res Cardiol 2010; 105: 205-218. doi: 10.1007/s00395-009-0076-5.
37. Jankowski M, Wang D, Danalache B, Gangal M, Gutkowska J. Cardiac oxytocin receptor blockade stimulates adverse cardiac remodeling in ovariectomized spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2010; 299: H265-H274. doi: 10.1152/ajpheart.00487.2009.
38. Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J. Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc Natl Acad Sci U S A 2002; 99: 9550-9555. doi: 10.1073/pnas. 152302499.
39. Oyama T, Nagai T, Wada H, Naito AT, Matsuura K, Iwanaga K, et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol 2007; 176: 329-341. doi: 10.1083/jcb.200603014.
40. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem 2004; 279: 11384-11391. doi: 10.1074/jbc.M310822200.
41. Gutkowska J, Paquette A, Wang D, Lavoie JM, Jankowski M. Effect of exercise training on cardiac oxytocin and natriuretic peptide systems in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R267-R275. doi: 10.1152/ajpregu.00071.2007.
42. Indrambarya T, Boyd JH, Wang Y, McConechy M, Walley KR. Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemiareperfusion injury in mice. Crit Care 2009; 13: R98. doi: 10.1186/cc7930.
43. Alizadeh AM, Faghihi M, Sadeghipour HR, Mohammadghasemi F, Khori V. Role of endogenous oxytocin in cardiac ischemic preconditioning. Regul Pept 2011; 167: 86-90. doi: 10.1016/j.regpep.2010.11.004.
44. Wsol A, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Kowalewski S, Dobruch J. Central oxytocin modulation of acute stress-induced cardiovascular responses after myocardial infarction in the rat. Stress 2009; 12: 517-525. doi: 10.3109/10253890802687688.
45. Nation DA, Szeto A, Mendez AJ, Brooks LG, Zaias J, Herderick EE, et al. Oxytocin attenuates atherosclerosis and adipose tissue inflammation in socially isolated ApoE-/-mice. Psychosom Med 2010; 72: 376-382. doi: 10.1097/ PSY.0b013e3181d74c48.
46. Norman GJ, Cacioppo JT, Morris JS, Malarkey WB, Berntson GG, DeVries AC. Oxytocin increases autonomic cardiac control: moderation by loneliness. Biol Psychol 2011; 86: 174-180. doi: 10.1016/j.biopsycho.2010.11.006.
47. Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008; 29: 1485-1494. doi: 10.1093/eurheartj/ ehn206.
48. Ishii H, Amano T, Matsubara T, Murohara T. Pharmacological intervention for prevention of left ventricular remodeling and improving prognosis in myocardial infarction. Circulation 2008; 118: 2710-2718. doi: 10.1161/CIRCU LATIONAHA.107.748772.
49. Mukaddam-Daher S, Yin YL, Roy J, Gutkowska J, Cardinal R. Negative inotropic and chronotropic effects of oxytocin. Hypertension 2001; 38: 292-296. doi: 10.1161/01.HYP.38.2.292.
50. Ondrejcakova M, Ravingerova T, Bakos J, Pancza D, Jezova D. Oxytocin exerts protective effects on in vitro myocardial injury induced by ischemia and reperfusion. Can J Physiol Pharmacol 2009; 87: 137-142. doi: 10.1139/Y08-108.
51. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010; 87: 406-423. doi: 10.1093/cvr/ cvq129.
52. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 2011; 90: 224-233. doi: 10.1093/cvr/cvr034.
53. Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre-and postconditioning. Herz 2008; 33: 88-100. doi: 10.1007/ s00059-008-3101-9.
54. Das B, Sarkar C. Is preconditioning by oxytocin administration mediated by iNOS and/or mitochondrial K(ATP) channel activation in the in vivo anesthetized rabbit heart? Life Sci 2012; 90: 763-769. doi: 10.1016/j.lfs.2012.03.030.
55. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011; 301: H2181-H2190. doi: 10.1152/ajpheart.00554.2011.
56. Wiemann M, Ehret G. Subcellular localization of immunoreactive oxytocin within thymic epithelial cells of the male mouse. Cell Tissue Res 1993; 273: 79-87. doi: 10.1007/ BF00304614.
57. Ndiaye K, Poole DH, Pate JL. Expression and regulation of functional oxytocin receptors in bovine T lymphocytes. Biol Reprod 2008; 78: 786-793. doi: 10.1095/biolreprod.107.065938.
58. Martens H, Kecha O, Charlet-Renard C, Defresne MP, Geenen V. Neurohypophysial peptides stimulate the phosphorylation of pre-T cell focal adhesion kinases. Neuroendocrinology 1998; 67: 282-289. doi: 10.1159/ 000054324.
59. Oliveira-Pelegrin GR, Saia RS, Carnio EC, Rocha MJ. Oxytocin affects nitric oxide and cytokine production by sepsis-sensitized macrophages. Neuroimmunomodulation 2013; 20: 65-71. doi: 10.1159/000345044.
60. Detillion CE, Craft TK, Glasper ER, Prendergast BJ, DeVries AC. Social facilitation of wound healing. Psychoneuroendocrinology 2004; 29: 1004-1011. doi: 10.1016/j.psyneuen.2003.10.003.
61. Iseri SO, Sener G, Saglam B, Gedik N, Ercan F, Yegen BC. Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils. J Surg Res 2005; 126: 73-81. doi: 10.1016/j.jss.2005.01.021.
62. Petersson M, Wiberg U, Lundeberg T, Uvnas-Moberg K. Oxytocin decreases carrageenan induced inflammation in rats. Peptides 2001; 22: 1479-1484. doi: 10.1016/S0196-9781(01)00469-7.
63. Amico JA, Mantella RC, Vollmer RR, Li X. Anxiety and stress responses in female oxytocin deficient mice. J Neuroendocrinol 2004; 16: 319-324. doi: 10.1111/j.0953-8194.2004.01161.x.
64. Bodi V, Sanchis J, Nunez J, Mainar L, Minana G, Benet I, et al. Uncontrolled immune response in acute myocardial infarction: unraveling the thread. Am Heart J 2008; 156: 1065-1073. doi: 10.1016/j.ahj.2008.07.008.
65. Al-Amran F, Shahkolahi M. Oxytocin ameliorates the immediate myocardial injury in rat heart transplant through downregulation of neutrophil-dependent myocardial apoptosis. Transplant Proc 2013; 45: 2506-2512. doi: 10.1016/j.transproceed.2013.03.022.
66. Dorge H, Schulz R, Belosjorow S, Post H, van De Sand A, Konietzka I, et al. Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol 2002; 34: 51-62. doi: 10.1006/jmcc.2001.1489.
67. Ebermann L, Piper C, Kuhl U, Klingel K, Schlattner U, Siafarikas N, et al. Impact of myocardial inflammation on cytosolic and mitochondrial creatine kinase activity and expression. Basic Res Cardiol 2009; 104: 247-257. doi: 10.1007/s00395-008-0773-5.
68. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 2008; 103: 485-492. doi: 10.1007/ s00395-008-0739-7.
69. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58: 88-111. doi: 10.1016/j.phrs. 2008.06.007.
70. Abdel-Latif A, Zuba-Surma EK, Case J, Tiwari S, Hunt G, Ranjan S, et al. TGF-beta1 enhances cardiomyogenic differentiation of skeletal muscle-derived adult primitive cells. Basic Res Cardiol 2008; 103: 514-524. doi: 10.1007/ s00395-008-0729-9.
71. Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 2001; 50: 609-613. doi: 10.1016/S0006-3223(01)01139-8.
72. Gassanov N, Devost D, Danalache B, Noiseux N, Jankowski M, Zingg HH, et al. Functional activity of the carboxyl-terminally extended oxytocin precursor peptide during cardiac differentiation of embryonic stem cells. Stem Cells 2008; 26: 45-54. doi: 10.1634/stemcells.2007-0289.
73. Gutkowska J, Jankowski M. Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol 2012; 24: 599-608. doi: 10.1111/j.1365-2826.2011.02235.x.
74. Gutkowska J, Jankowski M, Mukaddam-Daher S, McCann SM. Oxytocin is a cardiovascular hormone. Braz J Med Biol Res 2000; 33: 625-633. doi: 10.1590/S0100-879X2000 000600003.
75. McCann SM, Antunes-Rodrigues J, Jankowski M, Gutkowska J. Oxytocin, vasopressin and atrial natriuretic peptide control body fluid homeostasis by action on their receptors in brain, cardiovascular system and kidney. Prog Brain Res 2002; 139: 309-328. doi: 10.1016/S0079-6123(02)39027-7.